Eli Lilly and Co. will stop development of semagacestat, a gamma secretase inhibitor in Phase III development as a potential treatment for Alzheimer’s disease. Two ongoing Phase III studies showed the drug did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform daily activities. In the two Phase III trials, semagacestat was compared with placebo in more than 2,600 patients with mild-to-moderate Alzheimer’s dis...